Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity

The ability of myeloid regulatory cells (MRCs) to control immune responses and to promote tolerance has prompted enormous interest in exploiting them therapeutically to treat inflammation, autoimmunity, or to improve outcomes in transplantation. While immunomodulatory small-molecule compounds and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Parayath, N.N., Hao, S., Stephan, S.B., Koehne, A.L., Watson, C.E., Stephan, M.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599636/
https://www.ncbi.nlm.nih.gov/pubmed/34437913
http://dx.doi.org/10.1016/j.jconrel.2021.08.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599636/
https://www.ncbi.nlm.nih.gov/pubmed/34437913
http://dx.doi.org/10.1016/j.jconrel.2021.08.040

Ejemplares similares